Brian Thomas Hill MD PhD

Hematologic Oncology

Staff Physician, Cleveland Clinic - Taussig Cancer Institute

9500 Euclid Ave# TaussigCleveland, OH 44195
Phone+1 216-445-9451

Dr. Hill is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hill's full profile Already have an account?

Education & Training

Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2008 - 2011
University of ChicagoResidency, Internal Medicine, 2005 - 2008
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2005
State University of New YorkPh.D., Genetics, 2003
Dartmouth CollegeB.A., Biophysical Chemistry, Cum Laude, 1996

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

OH State Medical License 2008 - 2028
IL State Medical License 2005 - 2008

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2011, 2013-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2011, 2013-2017
CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2011, 2013-2017

Clinical Trials

Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
TERMINATED
PHASE1
Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant
COMPLETED
EARLY_PHASE1
Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma Start of enrollment: 2015 Jan 28
COMPLETED
PHASE1, PHASE2

Publications & Presentations

PubMed

1 citations
Neighborhood Socioeconomic Disadvantage and Distance From Treatment Center do not Impact Survival Outcomes of Patients With Non-Hodgkin Lymphoma and Multiple Myeloma T...
Agrima Mian, Rafaella Litvin, Danai Dima, Betty K Hamilton, Allison Winter
Transplantation and Cellular Therapy. 2026-10-01
TP53-Altered Aggressive Large B-Cell Lymphoma (LBCL) Outcomes by Treatment Modality: A Multicenter Cohort From 14 US Centers.
Cassandra Duarte, Grace N Bosma, Diana Abbott, Gaston Jean-Louis, Maciej Kabat
European Journal of Haematology. 2026-09-18
Bendamustine/Rituximab Induction Followed by Venetoclax/Rituximab Consolidation in Frontline Treatment of Chronic Lymphocytic Leukemia: A Phase 2 Multi-Center Study.
Andrew H Lipsky, Brian T Hill, Allison Winter, Spencer Henick Bachow, Naomi Sender
Hematological Oncology. 2026-07-01

Journal Articles

Effect of Bone Marrow CD34+Cells and T-cell Subsets on Clinical Outcomes After Myeloablative Allogeneic Hematopoietic Cell Transplantation
Deepa Jagadeesh, Matt Kalaycio, Brian Bolwell, Betty K Hamilton, Brian Hill, Brad Pohlman, Robert Dean, Navneet S Majhail, Sagar S Patel, Rabi Hanna, Aaron T Gerds, Ro..., Nature
Flow Cytometric Analysis of Cerebrospinal Fluid is Low Diagnostic Yield in Samples Without Atypical Morphology or Prior History of Hematologic Malignancy
Collie AMB, Hill BT, Stevens GHJ, Fenner K, Gazdick E, His ED, Am J. Clin. Path., 1/1/2014
Hamilton BK, Rybicki L, Dabney J, McLellan L, Haddad H, Foster L, Abounader D, Kalaycio M, Sobecks R, Dean R, Duong H, Hill BT, Bolwell BJ, Copelan EA, Bone Marrow Transplant, 1/1/2014

Books/Book Chapters

Clinical Ophthalmic Oncology
Chapter: Etiology of Cancer
Hill, BTEditors: Singh, AD and Damato, B.Springer-Verlag, Berlin & Heidelberg, GermanyEdition 2nd,2014

Abstracts/Posters

Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multi-Center Outcomes Analysis
Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (_ 70 Years...
Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Maintenance After Frontline Therapy in Follicular Lymphoma? An Appropriate Management Plan for...
ASCO Annual Meeting 2019 - Chicago, IL - 6/4/2019
Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Non-Hodgkin Lymphoma — Year in Review Series on Relevant New Datasets and AdvancesJune 5th, 2025
Evolving Frontline Therapy for Chronic Lymphocytic Leukemia (CLL)May 15th, 2025
$Real-World Insights on Bispecific Antibodies for Relapsed/Refractory Large B-cell Lymphomas$
Real-World Insights on Bispecific Antibodies for Relapsed/Refractory Large B-cell LymphomasFebruary 6th, 2025